150 related articles for article (PubMed ID: 30947366)
1. Drug Testing in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Zhao Z; Li X; El-Battrawy I; Lan H; Zhong R; Xu Q; Huang M; Liao Z; Lang S; Zimmermann WH; Cyganek L; Wieland T; Akin I; Zhou XB; Borggrefe M
Clin Pharmacol Ther; 2019 Sep; 106(3):642-651. PubMed ID: 30947366
[TBL] [Abstract][Full Text] [Related]
2. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Jæger KH; Wall S; Tveito A
PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
[TBL] [Abstract][Full Text] [Related]
3. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
4. Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Lan H; Xu Q; El-Battrawy I; Zhong R; Li X; Lang S; Cyganek L; Borggrefe M; Zhou X; Akin I
Front Pharmacol; 2020; 11():554422. PubMed ID: 33154722
[TBL] [Abstract][Full Text] [Related]
5. Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1.
Xu Q; Huang X; Meng Z; Li Y; Zhong R; Li X; Cyganek L; El-Battrawy I; Akin I; Zhou X; Lan H
J Cardiovasc Dev Dis; 2022 Apr; 9(4):. PubMed ID: 35448088
[TBL] [Abstract][Full Text] [Related]
6. Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
Huang M; Liao Z; Li X; Yang Z; Fan X; Li Y; Zhao Z; Lang S; Cyganek L; Zhou X; Akin I; Borggrefe M; El-Battrawy I
Front Pharmacol; 2021; 12():675003. PubMed ID: 34025432
[No Abstract] [Full Text] [Related]
7. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
[TBL] [Abstract][Full Text] [Related]
9. Human Induced Pluripotent Stem Cell-Derived Engineered Heart Tissue as a Sensitive Test System for QT Prolongation and Arrhythmic Triggers.
Lemoine MD; Krause T; Koivumäki JT; Prondzynski M; Schulze ML; Girdauskas E; Willems S; Hansen A; Eschenhagen T; Christ T
Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006035. PubMed ID: 29925535
[TBL] [Abstract][Full Text] [Related]
10. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
[TBL] [Abstract][Full Text] [Related]
11. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Profile of the Bradycardic Agent Ivabradine on Human Cardiac Ion Channels.
Haechl N; Ebner J; Hilber K; Todt H; Koenig X
Cell Physiol Biochem; 2019; 53(1):36-48. PubMed ID: 31169990
[TBL] [Abstract][Full Text] [Related]
13. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.
Sala L; Yu Z; Ward-van Oostwaard D; van Veldhoven JP; Moretti A; Laugwitz KL; Mummery CL; IJzerman AP; Bellin M
EMBO Mol Med; 2016 Sep; 8(9):1065-81. PubMed ID: 27470144
[TBL] [Abstract][Full Text] [Related]
14. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
[TBL] [Abstract][Full Text] [Related]
15. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
16. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
Brandão KO; van den Brink L; Miller DC; Grandela C; van Meer BJ; Mol MPH; de Korte T; Tertoolen LGJ; Mummery CL; Sala L; Verkerk AO; Davis RP
Stem Cell Reports; 2020 Nov; 15(5):1127-1139. PubMed ID: 33176122
[TBL] [Abstract][Full Text] [Related]
17. A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes.
Jæger KH; Edwards AG; Giles WR; Tveito A
PLoS Comput Biol; 2021 Aug; 17(8):e1009233. PubMed ID: 34383746
[TBL] [Abstract][Full Text] [Related]
18. Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
Millard D; Dang Q; Shi H; Zhang X; Strock C; Kraushaar U; Zeng H; Levesque P; Lu HR; Guillon JM; Wu JC; Li Y; Luerman G; Anson B; Guo L; Clements M; Abassi YA; Ross J; Pierson J; Gintant G
Toxicol Sci; 2018 Aug; 164(2):550-562. PubMed ID: 29718449
[TBL] [Abstract][Full Text] [Related]
19. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the heart's electrical properties by the anticonvulsant drug retigabine.
Rubi L; Kovar M; Zebedin-Brandl E; Koenig X; Dominguez-Rodriguez M; Todt H; Kubista H; Boehm S; Hilber K
Toxicol Appl Pharmacol; 2017 Aug; 329():309-317. PubMed ID: 28641963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
